ORMP (Oramed Pharmaceuticals) קצב צמיחת רווח למניה בשנה הנוכחית

The volatility of annual earnings per share demonstrates the ecological vector of Oramed Pharmaceuticals (ORMP), which eliminates the use of needles and syringes. Business stability relies on the patented POD system that protects proteins in the gastrointestinal tract. Today, 247.70 expresses the current value of the metric, highlighting the company's potential for pricing power driven by high demand among diabetics for innovative capsules over injections.

This indicator mathematically captures the dynamics of net profit per share, reflecting the efficiency of cash flow management. The metric measures the percentage deviation of current EPS from the previous year's value, uncovering hidden costs. For Oramed Pharmaceuticals (ORMP), this calculation is critical when scaling the development of oral insulin. By analyzing the annual growth of net profit per share in percentage terms on GURU.Markets, an investor assesses the financial stability of this biotech innovator.